Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joe Y Chang

Showing results (91-100 of 312) with videos related to

Pageof 32
Sort By:
Journal for Immunotherapy of Cancer|November 25, 2018
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitorsVivek Verma, Tanja Sprave, Waqar Haque, et al.
International Journal of Radiation Oncology, Biology, Physics|August 8, 2009
Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical studyXiaodong Zhang, Yupeng Li, Xiaoning Pan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 20, 2008
Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancerZhouguang Hui, Xiaodong Zhang, George Starkschall, et al.
International Journal of Particle Therapy|November 28, 2019
Trends and Outcomes of Proton Radiation Therapy Use for Non-Small Cell Lung CancerAmy C Moreno, Ning Zhang, Sharon H Giordano, et al.
Cancer Journal (Sudbury, Mass.)|July 22, 2016
Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid TumorsEric D Brooks, Jonathan E Schoenhals, Chad Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2006
Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptomsXin Shelley Wang, Diane L Fairclough, Zhongxing Liao, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2012
Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancerXu Zhang, Hui Liu, Peter Balter, et al.
Radiation Oncology (London, England)|June 3, 2014
Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trialZhengfei Zhu, Wei Liu, Michael Gillin, et al.
International Journal of Radiation Oncology, Biology, Physics|August 16, 2022
Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective TrialsHans Kim, Bhanu P Venkatesulu, Matthew T McMillan, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 6, 2016
Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcsJian-Yu Xu, Shan Lu, Xiang-Ying Xu, et al.
Pageof 32

Showing results (91-100 of 312) with videos related to

Sort By:
Pageof 32
Journal for Immunotherapy of Cancer|November 25, 2018
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitorsVivek Verma, Tanja Sprave, Waqar Haque, et al.
International Journal of Radiation Oncology, Biology, Physics|August 8, 2009
Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical studyXiaodong Zhang, Yupeng Li, Xiaoning Pan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 20, 2008
Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancerZhouguang Hui, Xiaodong Zhang, George Starkschall, et al.
International Journal of Particle Therapy|November 28, 2019
Trends and Outcomes of Proton Radiation Therapy Use for Non-Small Cell Lung CancerAmy C Moreno, Ning Zhang, Sharon H Giordano, et al.
Cancer Journal (Sudbury, Mass.)|July 22, 2016
Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid TumorsEric D Brooks, Jonathan E Schoenhals, Chad Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2006
Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptomsXin Shelley Wang, Diane L Fairclough, Zhongxing Liao, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2012
Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancerXu Zhang, Hui Liu, Peter Balter, et al.
Radiation Oncology (London, England)|June 3, 2014
Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trialZhengfei Zhu, Wei Liu, Michael Gillin, et al.
International Journal of Radiation Oncology, Biology, Physics|August 16, 2022
Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective TrialsHans Kim, Bhanu P Venkatesulu, Matthew T McMillan, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 6, 2016
Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcsJian-Yu Xu, Shan Lu, Xiang-Ying Xu, et al.
Pageof 32